The Study During October 30-November 4, 2009, Public Health Agency of Canada (PHAC) staff or private contractors collected blood from the chest or organs of hunted deer in 2 check stations in NS: Italy Cross (community A) and Lunenburg (community B) (Figure) . Hunters visiting a check station collected approximately 10% of all samples analyzed. Blood samples were collected from 82 deer (40 from community A, 42 from community B). All except 3 of the deer were harvested in zone 102 (https://novascotia.ca/ natr/draws/deerdraw/ddZones.asp#zone102) in southern NS, which includes community A and community B.
To evaluate prevalence of JCV among humans, we used residual human serum specimens submitted for prenatal screening and testing for cholesterol, electrolytes, or HIV during May 1-August 30, 2012, that had been used in a previous serosurvey (10) . We calculated sample size based on estimated seroprevalence of 20% among the NS population, with precision of ±5% and the ability to detect a statistically significant difference (p = 0.05) between District Health Authority (DHA) 1, DHA 9, and the remaining DHAs (Figure) . Because of high seropositivity among hunter-killed deer in DHA 1, humans were oversampled in DHA 1 to facilitate comparisons with other DHAs. We based human population estimates for 2012 on census data from Statistics Canada. We used Stata version 13.0 (StataCorp, College Station, TX, USA) for statistical analysis and used the Stata svy prefix command to incorporate sampling weights to produce estimates representative of the NS population. We stratified serum samples by age, sex, and DHA, with sampling proportionate to the NS population in 10-year age groups for those 10-59 years of age and a 5-year age group for those 60-64 years of age. We used Pearson χ 2 and corrected χ 2 statistics to test for significant differences based on DHA and sex, respectively. We used logistic regression to test for a significant increasing trend in seroprevalence by age group. The Research Ethics Board of each DHA approved the serosurvey; 1 board required an opt-out option by publicizing the study and asking patients to self-identify nonparticipation at the time of collection. No patient declined participation.
We shipped the samples to the National Microbiology Laboratory, where serum samples were stored at −80°C.
JCV antibodies in human and deer specimens were determined by using an arbovirus plaque-reduction neutralization assay (PRNT); a titer of >1:20 was considered positive (11) . Snowshoe hare virus (SSHV) or JCV and various dilutions of deer serum samples were incubated at 37°C for 1 h in tissue culture media, then added to Vero cell monolayers. After 1 hour of incubation at 37°C, an agar overlay was added; the plates were incubated in CO 2 for 3 days. An overlay containing neutral red was added to visualize plaque formation. Serum samples that inhibited >90% of plaque formation relative to virus controls, the highest positive serum dilution of the titration endpoint, were considered positive for viral antibodies. PRNT results were considered positive if the neutralizing antibody titer was >20; additional PRNT endpoint titrations were used to discriminate between related California serogroup viruses. Serum samples that demonstrated a 4-fold or greater difference in PRNT titers between SSHV and JCV were used to identify the virus to which the individual was previously exposed. JCV and SSHV strains used in PRNT assays were NY74-31 and SK75-93, respectively.
JCV antibody titers in samples from 72 of 82 deer ranged from 1:20 to >1:1,280; overall seroprevalence was 87.8% (95% CI 78.7%-94.0%; Table 1 ). Measured by using the Fisher exact test, seropositivity did not differ significantly based on sampling location, and JCV exposure did not differ by sex: 87.5% (35/40) of male deer and 91.9% (34/37) of female deer were seropositive (Table 1) . Seropositivity increased with age (75.0% of immature deer and 93.1% of adult deer were JCV-positive), but the difference was not statistically significant (p = 0.0567).
Of 301 human serum specimens tested for JCV antibodies, 81 were positive ( Table 2 ). After adjusting for survey design, the estimated overall seroprevalence for JCV in NS was 20.6% (95% CI 16.0%-25.9%). The DHA 1 seropositivity of 48.2% (95% CI 37.2%-59.1%) was significantly higher than those of DHAs 2-8 (combined seroprevalence: 22.6%, 95% CI 15.8%-31.4%) and that of DHA 9 (seroprevalence 15.2%, 95% CI 9.5%-23.5% [ Table 2 ]). Estimated seroprevalence was higher for men and boys than for women and girls (26.8% vs. 14.4%, respectively; p = 0.013) and increased with age (p = 0.024): 10.8% were seropositive among those 10-19 years of age, and 33% were seropositive among those 60-64 years of age (Table 2) .
Conclusions
In this study, we found that >20% of the tested residual serum samples of persons from Nova Scotia had antibody evidence of infection with JCV. The highest seroprevalence was 48% in specimens tested from 1 of the 9 DHAs. JCV antibodies were found in 88% of hunter-killed deer, higher than in studies in the United States (12, 13) .
A seroprevalence rate of 20.6% in persons living in NS is comparable to that seen in reports of other locations (14,15). The lowest rates of JCV in NS are in DHAs in which the province's 2 most populous cities, Halifax (DHA 9) and Sydney (DHA 8), are located. In addition to correlating JCV seropositivity with geographic location, this study demonstrated associations of seropositivity with male sex and increasing age in both sexes. These findings support prior data that identified increasing age as predictive for JCV infection, reporting an approximate 10-fold increase in JCV antibodies among persons in Alaska when comparing those <4 years of age with those >65 years of age (15). A limitation of this study is the relatively small number of serum samples, which may not represent the population at risk for this zoonotic disease. The use of anonymized residual serum samples did not enable us to collect data on outdoor activities, exposure history, or travel, so we cannot rule out the possibility that exposure to JCV occurred outside the respective DHA.
We provide serologic evidence of JCV infection in humans and deer in NS and suggest that central nervous system infections (e.g., viral encephalitis and viral meningitis) caused by JCV have been unrecognized. Until more is known of JCV's clinical effect in this province, evidence of its circulation should prompt consideration as a possible etiology of aseptic central nervous system disease. 
